Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance

Core Insights - Integra LifeSciences Holdings Corporation reported a GAAP net loss of $(1.7) million for Q4 2025, a significant decline from a net income of $19.4 million in Q4 2024, reflecting operational challenges and a goodwill impairment charge [5][14] - The company generated total revenues of $434.9 million in Q4 2025, a decrease of 1.7% from the same quarter in 2024, with organic revenues down 2.5% [5][9] - For the full year 2025, total reported revenues were $1,635.2 million, an increase of 1.5% compared to 2024, but organic sales decreased by 0.7% [9][13] Fourth Quarter 2025 Financial Summary - Total reported revenues for Q4 2025 were $434.9 million, down 1.7% from Q4 2024, with organic revenues decreasing by 2.5% [5][9] - The company reported a GAAP net loss of $(1.7) million, or $(0.02) per diluted share, compared to a net income of $19.4 million, or $0.25 per diluted share in Q4 2024 [5][9] - Adjusted EBITDA for Q4 2025 was $104.2 million, slightly down from $104.9 million in Q4 2024, with an adjusted EBITDA margin of 24.0% [6][9] Full-Year 2025 Financial Summary - Total reported revenues for the full year 2025 were $1,635.2 million, an increase of 1.5% from 2024, while organic sales decreased by 0.7% [9][13] - The company reported a GAAP net loss of $(516.5) million, or $(6.74) per diluted share, primarily due to a $511 million goodwill impairment charge [14][15] - Adjusted net income for the full year 2025 was $171.4 million, or $2.23 per diluted share, compared to $196.9 million, or $2.56 per diluted share in 2024 [15][9] Segment Performance - Codman Specialty Surgical, which accounts for 75% of revenues, reported total revenues of $323.3 million in Q4 2025, an increase of 2.7% on a reported basis [10][9] - Tissue Technologies, representing 25% of revenues, saw total revenues decline by 12.8% in Q4 2025, reflecting challenges in the Wound Reconstruction segment [12][9] Cash Flow and Capital Allocation - Cash flows from operations totaled $11.8 million in Q4 2025, with capital expenditures of $17.2 million [7][9] - For the full year 2025, the company generated cash flow from operations of $50.4 million, with capital expenditures amounting to $81.4 million [16][9] 2026 Guidance - For the full year 2026, the company expects revenues to range from $1,662 million to $1,702 million, indicating reported growth of 1.6% to 4.1% and organic growth of 0.8% to 3.3% [17][18] - Adjusted earnings per diluted share for 2026 are projected to be between $2.30 and $2.40 [17][18]